Fulcrum Therapeutics (FULC) Receives a Buy From Piper Sandler
Fulcrum Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Fulcrum Therapeutics, Maintains $23 Price Target
Fulcrum Therapeutics Analyst Ratings
Buy Rating Reaffirmed for Fulcrum Therapeutics Amid Sanofi Partnership and Promising Drug Prospects
Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target Is $15
Buy Rating Affirmed for Fulcrum Therapeutics: Licensing Deal With Sanofi and Promising Phase 3 Study
Fulcrum Upgraded by Goldman Sachs Ahead of Phase 3 Data
Fulcrum Therapeutics Analyst Ratings
Buy Rating Upheld for Fulcrum Therapeutics Amid Sanofi Partnership and Upcoming Trial Catalysts
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)
Fulcrum Therapeutics Analyst Ratings
Strong Buy Rating for Fulcrum Therapeutics Amidst Promising Clinical Progress and Financial Stability
Fulcrum Therapeutics Analyst Ratings
Oppenheimer Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC)
Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC), Ligand Pharma (LGND) and Alphatec Holdings (ATEC)
Stifel Nicolaus Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC)
Fulcrum Therapeutics Analyst Ratings
Fulcrum Therapeutics Analyst Ratings
Fulcrum Therapeutics Receives Buy Rating Amidst Promising Clinical Progress and Anticipated Data Readouts